Literature DB >> 2194419

Guillain-Barré syndrome: clinical and therapeutic observations.

G M McKhann1.   

Abstract

Better outcomes for patients with Guillain-Barré syndrome are associated with five factors: younger age, no requirement for respiratory assistance, slower progression of disease, normal peripheral nerve function by electrodiagnostic criteria, and treatment by plasmapheresis. Plasmapheresis is the only factor that the treating physician can modify. Consideration of the use of plasmapheresis in children, type of replacement fluid, plasma exchange by simpler methods than plasmapheresis, and possible alternative approaches to therapy are discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2194419     DOI: 10.1002/ana.410270705

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

Review 1.  Pathogenesis of neuroimmunologic diseases. Experimental models.

Authors:  C S Constantinescu; B Hilliard; T Fujioka; M K Bhopale; D Calida; A M Rostami
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barré syndrome.

Authors:  I Logina; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-10       Impact factor: 10.154

3.  The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid.

Authors:  H Brinkmeier; K H Wollinsky; P J Hülser; M J Seewald; H H Mehrkens; H H Kornhuber; R Rüdel
Journal:  Pflugers Arch       Date:  1992-09       Impact factor: 3.657

4.  High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study.

Authors:  M C Jackson; R B Godwin-Austen; A M Whiteley
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

5.  Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome.

Authors:  Jay M Meythaler; Robert C Brunner; Jean Peduzzi
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.